Related references
Note: Only part of the references are listed.Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
Laura W. Goff et al.
INVESTIGATIONAL NEW DRUGS (2019)
Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells
Muge Sak et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer A Randomized Clinical Trial
Gerald Falchook et al.
JAMA ONCOLOGY (2019)
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
Xiaofei Zhou et al.
INVESTIGATIONAL NEW DRUGS (2018)
A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer
Rie Kondo et al.
ONCOLOGY (2018)
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois et al.
CLINICAL CANCER RESEARCH (2018)
Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
Xiaofei Zhou et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Open-Label, Multicenter, Phase 1 Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, With Docetaxel in Patients With Solid Tumors
Julie N. Graff et al.
CANCER (2016)
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
Steven G. DuBois et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
Todd M. Pitts et al.
ONCOTARGET (2016)
Different schedules of irinotecan administration: A meta-analysis
Yi Shao et al.
MOLECULAR AND CLINICAL ONCOLOGY (2016)
Dose Selection for the Investigational Anticancer Agent Alisertib (MLN8237): Pharmacokinetics, Pharmacodynamics, and Exposure-Safety Relationships
Karthik Venkatakrishnan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
E. Claire Dees et al.
CLINICAL CANCER RESEARCH (2012)
Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB)
E. G. Lipsitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription Factor
Sandy Courapied et al.
MOLECULAR CANCER (2010)
Reducing irinotecan-associated diarrhea in children
Lars M. Wagner et al.
PEDIATRIC BLOOD & CANCER (2008)
A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia
Takayuki Ikezoe et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical implication of centrosome amplification in plasma cell neoplasm
WJ Chng et al.
BLOOD (2006)
Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma
E Camacho et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Share Paper
